Abstract
Background: Targeted Lung Denervation (TLD) is a novel bronchoscopic therapy that disrupts parasympathetic pulmonary nerve input to the lung to reduce clinical consequences of neural hyperactivity. Here the one-year safety and efficacy on crossover patients of the AIRFLOW-2 trial are evaluated.
Methods: TLD was performed in COPD patients (FEV1 30-60% pred, CAT≥10 or mMRC≥2) in a double-blind, 1:1 randomized, sham-controlled, multicenter study (NCT02058459) using TLD (Nuvaira, Inc., USA). Following the 12M follow-up visit, patients in the sham group were offered TLD treatment (crossover group). The impact of TLD on AECOPDs and lung function was analyzed in crossover patients 12M after treatment.
Results: 20 sham-controlled patients (50.0% male, age 64.1±6.8 yrs) received TLD and crossed over; 15 have completed 12M follow-up. Following the TLD procedure, the % of patients with a moderate or severe AECOPD and severe AECOPD decreased from 73% to 47% and 25% to 13%, respectively. Time-to-first event for moderate and severe AECOPD, and severe AECOPD was also attenuated by TLD (Figure). Lung function remained stable. All data is preliminary.
Conclusion: Fewer patients experienced a moderate or severe AECOPD in the year following treatment compared to their own prior year exacerbation history. The impact on exacerbations following crossover are consistent with outcomes observed during the randomization phase.
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3775.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020